HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 agonists and SGLT2 inhibitors linked to lower dementia risk in type 2 diabetes

Louis Nervegna · Apr 13, 2025 · ♥ 6 reactions · 1 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Brain health & dementiaInsulin resistance & diabetes
AI summary & key facts

JAMA Neurology report shared by Louis: in people with type 2 diabetes, both GLP-1 receptor agonists and SGLT2 inhibitors were associated with decreased risk of Alzheimer disease and related dementias compared with other glucose-lowering drugs. Louis sees this as evidence for benefits beyond diabetes treatment.

More evidence for benefits of GLP-1 agonists and SGLT2 inhibitors that go well beyond just treating diabetes.

#dementiaHD #alzheimersHD #sglt2HD #glucoseHD #diabetesHD #sglt2dementiaHD

Research cited

Most viewed in the last 7 days from JAMA Neurology: In people with type 2 diabetes, both GLP-1RAs and SGLT2is were associated with decreased risk of Alzheimer disease and related dementias vs other glucose-lowering drugs.

Paper · JAMA NeurologyJAMA Neurology articleja.maNo photo description available.
← newer: CORDIOPREV: Mediterranean diet reversed carotid plaque and colder: Commentary on a public figure's reported labs (LDL 51 on ros →